Investor Relations (IR) Questions: Ohr Pharmaceuticals OHRP
Click here to return to the biotech IRQ Index
Answers received: March 2013
1) When is the last time OHRP raised cash through an offering (diluted)? Our last raise was achieved through the exercise of warrants in June 2012 for proceeds of approximately $2.9mm.
2) How much cash (not cash equivalents) does OHRP have? As of our last quarterly filing, we have approximately $2.07mm in cash.
3) What and approximately when is the next known catalyst? Our next anticipated milestones are the release of data before the end of this quarter on a phase II trial in cancer cachexia for our OHR/AVR118 product and an uplisting to a national exchange in the middle of the year.
4) What is OHRP's quarterly cash burn? Approximately $500k per quarter
5) Does OHRP have an existing line of credit and if so how much can they draw against it? Ohr does not currently have a line of credit.
Please feel free to reach out to me if you have any further questions.
Best regards,
Sam
Sam Backenroth
Chief Financial Officer
Ohr Pharmaceutical Inc
1) When is the last time OHRP raised cash through an offering (diluted)? Our last raise was achieved through the exercise of warrants in June 2012 for proceeds of approximately $2.9mm.
2) How much cash (not cash equivalents) does OHRP have? As of our last quarterly filing, we have approximately $2.07mm in cash.
3) What and approximately when is the next known catalyst? Our next anticipated milestones are the release of data before the end of this quarter on a phase II trial in cancer cachexia for our OHR/AVR118 product and an uplisting to a national exchange in the middle of the year.
4) What is OHRP's quarterly cash burn? Approximately $500k per quarter
5) Does OHRP have an existing line of credit and if so how much can they draw against it? Ohr does not currently have a line of credit.
Please feel free to reach out to me if you have any further questions.
Best regards,
Sam
Sam Backenroth
Chief Financial Officer
Ohr Pharmaceutical Inc